John J. Molenda

Richard T. Ruzich

Brian P. Murray

Stephen R. Auten

Kenneth L. Dorsney

Vishal C. Gupta

John C. Phillips, Jr.

David A. Bilson

Ryan O. White

Amy K. Wigmore

Andrew J. Danford

Kevin M. Yurkerwich

Tracey C. Allen

Brian E. Farnan

Gregory H. Lantier

Michael J. Farnan

Jeffrey T. Hantson

Timothy A. Cook

Heather M. Petruzzi

ANDA filing triggers BMS/Pfizer lawsuit to block generic Eliquis®, accusing Apotex over `apixaban compound` and `particle size distribution` patent claims.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Bristol-Myers Squibb Co	L4 A
Pfizer Inc	L5 A

Name	Ratings
Wilmer Cutler Pickering Hale Dorr LLP	L5 A
Gregory H. Lantier	L3 A
Amy K. Wigmore	L3 E
Tracey C. Allen	L2 B
Andrew J. Danford	L1 D
Heather M. Petruzzi	L1 E
Kevin M. Yurkerwich	-- -- --
Jeffrey T. Hantson	-- -- --
Timothy A. Cook	-- -- --
Farnan LLPLocal	L4 E
Brian E. Farnan	L5 E
Michael J. Farnan	L5 E

Name	Ratings
Apotex Inc	L5 E
Apotex Corp	L5 E

Name	Ratings
Morris James LLPLocal	L4 E
Kenneth L. Dorsney	L5 E
Richard T. Ruzich	L1 E
Steptoe & Johnson LLP	L3 E
John J. Molenda	L2 B
Vishal C. Gupta	L1 B
Taft Stettinius & Hollister LLP	L3 E
Stephen R. Auten	L3 E
Brian P. Murray	L2 D
Ryan O. White	-- -- --
Phillips Goldman McLaughlin & Hall PALocal	L3 E
John C. Phillips, Jr.	L5 E
David A. Bilson	L5 E

1:17-cv-00399

Bristol Myers Squibb Co v. Apotex Inc